Rein Therapeutics Inc.
RNTX
$1.45
$0.053.57%
NASDAQ
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 3.23% | 5.36% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -3.24% | -4.51% | |||
| Operating Income | 3.24% | 4.51% | |||
| Income Before Tax | 87.06% | -627.30% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 86.58% | -600.89% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 86.58% | -600.89% | |||
| EBIT | 3.24% | 4.51% | |||
| EBITDA | 3.51% | 4.51% | |||
| EPS Basic | 86.71% | -599.93% | |||
| Normalized Basic EPS | 1.44% | 5.63% | |||
| EPS Diluted | 86.71% | -599.93% | |||
| Normalized Diluted EPS | 1.44% | 5.63% | |||
| Average Basic Shares Outstanding | 1.03% | 0.14% | |||
| Average Diluted Shares Outstanding | 1.03% | 0.14% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||